Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease

Journal of Nutritional Biochemistry

Volumn 26, Issue 10, 2015, Pages 996-1006

  Tallino, Savannah ^a   Duffy, Megan ^b   Ralle, Martina ^b   Cortés, María Paz ^c   Latorre, Mauricio ^c   Burkhead, Jason L ^a  

^a UNIVERSITY OF ALASKA ANCHORAGE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CHILE   (Chile)

Author keywords

Copper; Fibrosis; Inflammation; Liver; Nonalcoholic steatohepatitis; Steatosis

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; FATTY ACID SYNTHASE; SUCROSE; COPPER; SUGAR INTAKE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; COPPER DEFICIENCY; GENE EXPRESSION; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPOGENESIS; LIVER FIBROSIS; LIVER INJURY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRIGENOMICS; RAT; STELLATE CELL; SUGAR INTAKE; UPREGULATION; ADVERSE EFFECTS; ANIMAL; DEFICIENCY; DIET; DISEASE MODEL; GENETICS; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; COPPER; DIET; DIETARY SUCROSE; DISEASE MODELS, ANIMAL; GENE EXPRESSION; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPOGENESIS; LIVER; LIVER CIRRHOSIS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRIGENOMICS; RATS; RATS, WISTAR;

EID: 84942551023     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2015.04.009     Document Type: Article

References (75)

1. McArdle M.A., Finucane O.M., Connaughton R.M., McMorrow A.M., Roche H.M. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol (Lausanne) 2013, 4:52. 10.3389/fendo.2013.00052.
2. Torres D.M., Harrison S.A. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008, 134:1682-1698.
3. Ogden C.L., Carroll M.D., Kit B.K., Flegal K.M. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief 2012, 1-8.
4. Baker R.G., Hayden M.S., Ghosh S. NF-kB, inflammation, and metabolic disease. Cell Metab 2011, 13:11-22.
5. Eckel R.H., Alberti K.G.M.M., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
6. Weston S.R., Leyden W., Murphy R., Bass N.M., Bell B.P., Manos M.M., et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005, 41:372-379.
7. Attar B.M., Van Thiel D.H. Current concepts and management approaches in nonalcoholic fatty liver disease. Sci World J 2013, 1-10.
8. Naik A., Košir R., Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics 2013, 102:84-95.
9. Lazo M., Hernaez R. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011, 343:1-9.
10. Trauner M., Arrese M., Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta 1801, 2010:299-310.
11. Nobili V., Siotto M., Bedogni G., Ravà L., Pietrobattista A., Panera N., et al. Levels of serum ceruloplasmin associate with pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2013, 56:370-375.
12. Roberts E.A. Pediatric nonalcoholic fatty liver disease (NAFLD): a "growing" problem?. J Hepatol 2007, 46:1133-1142.
13. Cohen-Naftaly M., Friedman S.L. Current status of novel antifibrotic therapies in patients with chronic liver disease. Ther Adv Gastroenterol 2011, 4:391-417.
14. Lim J.S., Mietus-Snyder M., Valente A., Schwarz J.-M., Lustig R.H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010, 7:251-264.
15. Pais R., Charlotte F., Fedchuk L., Bedossa P., Lebray P., Poynard T., et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013, 59:550-556.
16. Paradis V., Bedossa P. Definition and natural history of metabolic steatosis: histology and cellular aspects. Diabetes Metab 2008, 34:638-642.
17. Standish R.A., Cholongitas E., Dhillon A., Burroughs A.K., Dhillon A.P. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006, 55:569-578.
18. Angulo P., Bugianesi E., Bjornsson E.S., Charatcharoenwitthaya P., Mills P.R., Barrera F., et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013, 145:782-789.
19. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
20. Burkhead JL, Lutsenko S. The role of copper as a modifier of lipid metabolism. In: Prof. Rodrigo Valenzuela Baez (Ed.) Lipid metabolism 2013, InTech, (Rijeka).
21. Collins J.F., Klevay L.M. Copper 1,2. Adv Nutr Res 2011, 2:520-522.
22. Aigner E., Theurl I., Haufe H., Seifert M., Hohla F., Scharinger L., et al. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 2008, 135:680-688.
23. Aigner E., Strasser M., Haufe H., Sonnweber T., Hohla F., Stadlmayr A., et al. A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease. Am J Gastroenterol 2010, 105:1978-1985.
24. Song M., Schuschke D.A., Zhou Z., Chen T., Pierce W.M., Wang R., et al. High fructose feeding induces copper deficiency in Sprague-Dawley rats: a novel mechanism for obesity related fatty liver. J Hepatol 2012, 56:433-440.
25. Song M., Schuschke D.A., Zhou Z., Chen T., Shi X., Zhang J., et al. Modest fructose beverage intake causes liver injury and fat accumulation in marginal copper deficient rats. Obesity (Silver Spring) 2013, 000:1-7.
26. Maliken B.D., Nelson J.E., Klintworth H.M., Beauchamp M., Yeh M.M., Kowdley K.V. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology 2013, 57:1806-1813.
27. Nose Y., Kim B.E., Thiele D.J. Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. Cell Metab 2006, 4:235-244.
28. Yu Z., Lowndes J., Rippe J. High-fructose corn syrup and sucrose have equivalent effects on energy-regulating hormones at normal human consumption levels. Nutr Res 2013, 33:1043-1052.
29. Keim N.L., Havel P.J. Fructose - absorption and metabolism. Encycl. Hum. Nutr. 2013, vol. 2:361-365. 3rd ed. B. Caballero (Ed.).
30. Vos M., Kimmons J., Gillespie C., Welsh J., Blanck H. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey (NHANES III). Medscape J Med 2008, 10:160.
31. Abid A., Taha O., Nseir W., Farah R., Grosovski M., Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 2009, 51:918-924.
32. Yang Q., Zhang Z., Gregg E.W., Flanders W.D., Merritt R., Hu F.B. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med 2014, 174:516-524.
33. Yilmaz Y. Review article: fructose in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012, 35:1135-1144.
34. Committee Guide for the care and use of laboratory animals. Guid. Care Use Lab. Anim 2011, 41-75. Eighth ed.
35. McCarthy D.J., Smyth G.K. Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics 2009, 25:765-771.
36. Wang J., Duncan D., Shi Z., Zhang B. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res 2013, 41:W77-W85. [web server issue].
37. Zhang B., Kirov S., Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005, 33:W741-W748.
38. Ruijter J.M., Ramakers C., Hoogaars W.M.H., Karlen Y., Bakker O., van den hoff M.J.B., et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res 2009, 37:e45.
39. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
40. Yeh M.M., Brunt E.M. Pathology of fatty liver: differential diagnosis of non-alcoholic fatty liver disease. Diagn Histopathol 2008, 14:586-597.
41. Le T.T., Ziemba A., Urasaki Y., Brotman S., Pizzorno G. Label-free evaluation of hepatic microvesicular steatosis with multimodal coherent anti-Stokes Raman scattering microscopy. PLoS One 2012, 7(11):e51092.
42. Cacho J., Sevillano J., de Castro J., Herrera E., Ramos M.P. Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. Am J Physiol Endocrinol Metab 2008, 295:E1269-E1276.
43. Jaccard J., Becker M.A., Wood G. Pairwise multiple comparison procedures: a review. Psychol Bull 1984, 96:589-596.
44. Motulsky H.J., Brown R.E. Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 2006, 7:123.
45. Chiappini F., Barrier A., Saffroy R., Domart M.-C., Dagues N., Azoulay D., et al. Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray. Lab Invest 2006, 86:154-165.
46. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
47. Levene A.P., Kudo H., Armstrong M.J., Thursz M.R., Gedroyc W.M., Anstee Q.M., et al. Quantifying hepatic steatosis - more than meets the eye. Histopathology 2012, 60:971-981.
48. Ogra Y., Suzuki K.T. Targeting of tetrathiomolybdate on the copper accumulating in the liver of LEC rats. J Inorg Biochem 1998, 70:49-55.
49. Suzuki K.T., Ogra Y., Ohmichi M. Molybdenum and copper kinetics after tetrathiomolybdate injection in LEC rats: specific role of serum albumin. J Trace Elem Med Biol 1995, 9:170-175.
50. Kanuri G., Bergheim I. In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci 2013, 14:11963-11980.
51. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
52. Sookoian S., Gianotti T.F., Rosselli M.S., Burgueño A.L., Castaño G.O., Pirola C.J. Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 2011, 218:378-385.
53. Ferder L., Ferder M.D., Inserra F. The role of high-fructose corn syrup in metabolic syndrome and hypertension. Curr Hypertens Rep 2010, 12:105-112.
54. Aronne L.J., Nelinson D.S., Lillo J.L. Obesity as a disease state: a new paradigm for diagnosis and treatment. Clin Cornerstone 2009, 9:9-25. [discussion 26-9].
55. Wang Y., Lam K.S.L., Kraegen E.W., Sweeney G., Zhang J., Tso A.W.K., et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007, 53:34-41.
56. Xu G., Ahn J., Chang S., Eguchi M., Ogier A., Han S., et al. Lipocalin-2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation. J Biol Chem 2012, 287:4808-4817.
57. Dittrich A.M., Meyer H.A., Hamelmann E. The role of lipocalins in airway disease. Clin Exp Allergy 2012, 43:503-511.
58. Catalán V., Gómez-Ambrosi J., Rodríguez A., Ramírez B., Rotellar F., Valentí V., et al. Six-transmembrane epithelial antigen of prostate 4 and neutrophil gelatinase-associated lipocalin expression in visceral adipose tissue is related to iron status and inflammation in human obesity. Eur J Nutr 2013, 52:1587-1595.
59. Lake A.D., Novak P., Shipkova P., Aranibar N., Robertson D., Reily M.D., et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol 2013, 268:132-140.
60. Zakaria S., Youssef M., Moussa M., Akl M., El-Ahwany E., El-Raziky M., et al. Value of α-smooth muscle actin and glial fibrillary acidic protein in predicting early hepatic fibrosis in chronic hepatitis C virus infection. Arch Med Sci 2010, 6:356-365.
61. Carotti S., Morini S., Corradini S.G., Burza M.A., Molinaro A., Carpino G., et al. Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl 2008, 14:806-814.
62. Yi H.-S., Jeong W.-I. Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend?. J Gastroenterol Hepatol 2013, 28(Suppl. 1):99-104.
63. Xie G., Karaca G., Swiderska-Syn M., Michelotti G.A., Krüger L., Chen Y., et al. Cross-talk between notch and hedgehog regulates hepatic stellate cell fate 2013.
64. Omenetti A., Porrello A., Jung Y., Yang L., Popov Y., Choi S.S., et al. Report information from ProQuest. J Clin Invest 2008, 118:3331-3342.
65. Yu L., Border W.A., Huang Y., Noble N.A. TGF-beta isoforms in renal fibrogenesis. Kidney Int 2003, 64:844-856.
66. Kimura C., Hayashi M., Mizuno Y., Oike M. Endothelium-dependent epithelial-mesenchymal transition of tumor cells: exclusive roles of transforming growth factor β1 and β2. Biochim Biophys Acta 1830, 2013:4470-4481.
67. Sreekumar R., Rosado B., Rasmussen D., Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003, 38:244-251.
68. Menendez J.A., Vazquez-Martin A., Ortega F.J., Fernandez-Real J.M. Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clin Chem 2009, 55:425-438.
69. Lanaspa M.A., Sanchez-Lozada L.G., Choi Y.-J., Cicerchi C., Kanbay M., Roncal-Jimenez C.A., et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem 2012, 287:40732-40744.
70. Nelson D., Cox M.M. Lehninger principles of biochemistry 2004, 4th ed.
71. Kawano Y., Cohen D.E. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 2013, 48:434-441.
72. Postic C., Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008, 118:829-838.
73. Kuntz E., Kuntz H.-D. Hepatology 2008, 3rd ed.
74. Chun O.K., Chung C.E., Wang Y., Padgitt A., Song W.O. Changes in intakes of total and added sugar and their contribution to energy intake in the U.S. Nutrients 2010, 2:834-854.
75. Prevention C for DC and. Trends in intake of energy and macronutrients - United States, 1971-2000. Morb Mortal Wkly Rep 2004, 53:80-82.